Post Partum Hemorrhage
Conditions
Brief summary
Caesarean delivery is inevitably associated with a higher amount of blood loss vis-à-vis primary postpartum haemorrhage, when compared to vaginal delivery. Oxytocin use in tropical developing countries for the reduction blood loss at caesarean section have been met with challenges of ineffectiveness due to poor transportation, inadequate storage and drug adulteration. Therefore, there is a need for an effective, temperature stable uterotonic with a lesser risk of adulteration. The study is aimed at evaluating the effectiveness and safety of adjunctive sublingual misoprostol in reducing intraoperative blood loss at caesarean section.
Detailed description
It would be a double blind randomized controlled trial. One hundred and fifty-two pregnant women at term who have indications for caesarean section and have risk factors for primary postpartum haemorrhage, as well as meet the eligibility criteria would be randomized equally into two study arms (Misoprostol study arm and Placebo study arm) after informed consent. The Misoprostol study arm will receive 400 mcg of sublingual misoprostol as two 200 mcg misoprostol tablets. The Placebo study arm would receive two sublingual placebo tablets similar to the misoprostol tablets. The Misoprostol and the Placebo tablets will be given in each study arm at the point of starting the uterine incision at caesarean section. Both study arms would receive routine intravenous oxytocin at the time of clamping of the umbilical cord. The outcome measures will be estimated intraoperative blood loss, the need for additional intraoperative oxytocic, blood transfusion, the occurrence of side effects, and incidence of primary postpartum haemorrhage.
Interventions
DRUGMisoprostol
The misoprostol tablets to be used in the study will be of the same brand and batch
DRUGOxytocin
The oxytocin ampoules to be used in the study will be of the same brand and batch
Sponsors
OZORI EBIOGBO STANLEY
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
A hospital's pharmacist/pharmacologist will manufacture the misoprostol tablets at doses of 200 mcg each as well as the placebo tablets (which will contain vitamin B complex excipient only). The misoprostol tablets and placebo tablets will be indistinguishable. Envelopes will be pre-packed, sealed and outwardly labelled by a hospital's pharmacist/pharmacologist who will take no further part in the study. Each pre-packed envelope will contain three 200 mcg misoprostol tablets for the misoprostol arm or three placebo tablets (which will contain vitamin B complex excipient only) for the placebo arm. The randomization list will be in the possession of a research assistant who will take no further part in the study after randomly allocating the participants to the study arms, till the end of the study.
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Pregnant women at term (37+0 weeks to 41+6 weeks gestational age) for elective or non-elective caesarean sections * Pregnant women who have risk factor for primary postpartum haemorrhage * Pregnant women who consent to participate in the study
Exclusion criteria
* Pregnant women who withhold consent to participate in the study * Caesarean sections for dire emergencies (umbilical cord prolapse, suspected fetal distress and active antepartum haemorrhage) * Previous caesarean sections or other uterine surgeries * Pregnant women with no risk factor for primary postpartum haemorrhage * Allergy to misoprostol use * Known history of hepatic, renal and haematological disorders * Caesarean section to be done under general anaesthesia * Fever (temperature ≥ 37.5 degrees centigrade) * Pre-operative anaemia (pre-operative haematocrit level \< 30 %) * Pregnant women who are unconscious or have eclampsia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimated volume of intraoperative blood loss | Immediate postoperative period | Intraoperative blood loss would be estimated by standard volumetric and gravimetric methods using standard calibrated suction bottles for the volumetric method and for the gravimetric method; wet weight of the abdominal mops, delivery mats, theatre drapes, theatre gowns and vaginal swabs will be gotten using the Mettler PB 153 weighing scale after its re-calibration. The total estimated intraoperative blood loss (T) will be measured by calculating the sum total of the weights of the blood soaked abdominal mops, vaginal gauzes, theatre drapes, theatre gowns and delivery mat (S) and subtracting the sum total of the dry weights of the used abdominal mops, vaginal gauzes, theatre drapes, theatre gowns and delivery mat (D) as shown in the equation: T = S - D. It will be assumed that 1 ml of blood weighs approximately 1 g |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Side effect profile | From intraoperative administration of the study intervention till 4 hours postoperative | Side effect including nausea, vomiting, fever, and shivering |
| Postoperative haematocrit level | At 48 hours postoperative | 48 hours postoperative haematocrit level |
| Additional intraoperative oxytocic | From intraoperative administration of the study intervention till 4 hours postoperative | Additional intraoperative oxytocic as10 IU oxytocin when there is absence of uterine tone as assessed by the lead surgeon ten minutes after administration of the intervention drug. Intramuscular ergometrine at a dose of 0.5 mg will be used as a second-line additional uterotonic agent where there are no contraindications. |
| Postoperative blood transfusion | From intraoperative administration of the study intervention till 48 hours postoperative | Postoperative blood transfusion indicated by occurrence of primary postpartum haemorrhage (an intraoperative blood loss ≥ 1,000 ml following caesarean section or symptomatic postoperative haematocrit level ≤ 24 %) |
Countries
Nigeria
Contacts
Primary ContactStanley E Ozori
Outcome results
None listed